XZXingzhi Zhou

Xingzhi Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xingzhi Zhou has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Jiazhuo Liu

    Engineering Technology Research Center for Functional Component Utilization of Organic Natural Products, Medical College, Dalian University, Dalian, Liaoning, China

    1 shared publication
  • Ran Tao

    Department of Anatomy, Medical College, Dalian University, Dalian, Liaoning, China

    1 shared publication
  • Shuangping Liu

    Department of Pathology, Medical School, Dalian University, Dalian, China

    1 shared publication
  • Teng Zou

    Engineering Technology Research Center for Functional Component Utilization of Organic Natural Products Medical College Dalian University Dalian Liaoning China

    1 shared publication
  • Yisong Yang

    Engineering Technology Research Center for Functional Component Utilization of Organic Natural Products Medical College Dalian University Dalian Liaoning China

    1 shared publication
  • Yiting Liu

    Engineering Technology Research Center for Functional Component Utilization of Organic Natural Products Medical College Dalian University Dalian Liaoning China

    1 shared publication

Latest Publications

  • Open Access

    HMGCR: a malignancy hub - frontiers in cancer diagnosis and therapy

    by Yisong Yang, Yiting Liu, Teng Zou, Jiazhuo Liu, Xingzhi Zhou, Ran Tao, Shuangping Liu

    Cholesterol metabolism is significantly activated during most tumor growth. As a key rate-limiting enzyme in cholesterol synthesis, HMG-CoA reductase (HMGCR) affects tumor metabolic reprogramming by upregulating cholesterol metabolism and promotes tumor growth and immune escape by remodeling the tumor microenvironment. It fuels tumor growth by providing cholesterol and isoprenoids, regulating critical pathways (Hippo, Hedgehog, MAPK), and modulating ferroptosis sensitivity. A complex bidirectional relationship exists between HMGCR and the pro-inflammatory cytokine TNF-α: TNF-α can inhibit HMGCR activity and thus inhibit cholesterol synthesis. At the same time, HMGCR influences TNF-αmediated inflammation and immune evasion. Statins, as HMGCR inhibitors, have shown anti-tumor effects in experiments. However, clinical application faces challenges including highly toxic concentration, drug resistance and tissue specificity. Accordingly, further exploration of mechanism-based targeted precision therapies to intervene in the HMGCR-TNF-α axis and related pathways, as well as the development of novel HMGCR inhibitors or optimization of existing drugs, represents an innovative strategy to enhance cancer treatment efficacy and advance drug development.